| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CI-976 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.6 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | PD318088 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | AZD7762 | GDSC1000 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.029 | 0.6 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | BRD-K04800985 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | -0.039 | 0.6 |
| mRNA | Bosutinib | GDSC1000 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |